[References]　Targeting DNA Repair Mechanisms: Exploiting Acquired Vulnerabilities to Overcome Resistance in Cholangiocarcinoma

  1. M. Squadroni, L. Tondulli, G. Gatta, S. Mosconi, G. Beretta, R. Labianca, “Cholangiocarcinoma”, Crit. Rev. Oncol. Hematol., 2017, 116, 11-31.
  2. P. J. Brindley, M. Bachini, S. I. Ilyas, S. A. Khan, A. Loukas, A. E. Sirica, B. T. Teh, S. Wongkham, G. J. Gores, “Cholangiocarcinoma”, Nat. Rev. Dis. Primers, 2021, 7(1), 65.
  3. A. Scheiter et al., “Wnt/β-Catenin-Pathway Alterations and Homologous Recombination Deficiency in Cholangiocarcinoma Cell Lines and Clinical Samples: Towards Specific Vulnerabilities”, J. Pers. Med., 2022, 12(8), 1282.
  4. P. G. Pilié et al., “State-of-the-art strategies for targeting the DNA damage response in cancer”, Nat. Rev. Clin. Oncol., 2019, 16(2), 81-104.
  5. A. D. D'Andrea, “Mechanisms of PARP inhibitor sensitivity and resistance”, DNA Repair (Amst), 2018, 71, 172-176.
  6. D. Slade, “PARP and PARG inhibitors in cancer treatment”, Genes Dev., 2020, 34(5-6), 360-394.
  7. H. Gaillard et al., “Replication stress and cancer”, Nat. Rev. Cancer, 2015, 15(5), 276-289.
  8. A. da Costa et al., “Targeting replication stress in cancer therapy”, Nat. Rev. Drug Discov., 2022, 21(6), 463-482.
  9. T. Lerksuthirat et al., “DNA Damage and Repair Activities of Crude Secondary Metabolite Extracts from Guignardia bidwellii Obtained from the Leaf of Garcinia cowa”, BMC Complement. Med. Ther., 2020, 20, 142.
  10. S. A. Yazinski et al., “ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells”, Genes Dev., 2017, 31(3), 318-332.
  11. P. C. Fong et al., “Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers”, N. Engl. J. Med., 2009, 361(2), 123-134.
  12. Y.-Y. Chu et al., “Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors”, J. Biomed. Sci., 2022, 29, 19.
  13. D. E. Spratt et al., “Translational and clinical implications of the genetic landscape of prostate cancer”, Nat. Rev. Clin. Oncol., 2016, 13(10), 597-610.
  14. S. Prasopporn et al., “Combining the SMAC mimetic LCL161 with gemcitabine plus cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma”, Front. Oncol., 2022, 12, 1021632.
  15. S. Jamnongsong et al., “Comprehensive drug response profiling and pan-omic analysis identified therapeutic candidates and prognostic biomarkers for Asian cholangiocarcinoma”, iScience, 2022, 25(10), 105182.
  16. G. Smith et al., “DNA Damage Repair Inhibitors — Combination Therapies”, Cancer J., 2021, 27(6), 501-505.
  17. E. K. Lee, U. A. Matulonis, “PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies”, Cancers (Basel), 2020, 12(8), 2054.
  18. D. Bhamidipati et al., “PARP inhibitors: enhancing efficacy through rational combinations”, Br. J. Cancer, 2023, 129(6), 904-916.
  19. T. Lerksuthirat et al., “DNA damage response mutations enhance the antitumor efficacy of ATR and PARP inhibitors in cholangiocarcinoma cell lines”, Oncol. Lett., 2025, 29(3), 128.
  20. R. Wikiniyadhanee et al., “ATR inhibitor synergizes PARP inhibitor cytotoxicity in homologous recombination repair-deficient TK6 cell lines”, Biomed Res. Int., 2023, 2023, 7891753.
前のページへ戻る
TOP